{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-106421","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.842176+00:00","generated_at":"2026-05-17T00:32:41.923329+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cryoport Q3 revenue rises 15% to $44.2M; raises FY2025 guidance to $170-174M","bullets":["Q3 continuing ops revenue $44.2M (+15% YoY); gross margin 48.2% vs 45.5%.","Commercial Cell & Gene Therapy revenue up 36% YoY to $8.3M; supported 19 commercial therapies.","GAAP net loss attributable to common stockholders $8.9M ($0.18 loss per share) in Q3.","Adjusted EBITDA from continuing ops improved to -$0.6M from -$2.7M; cash/investments $421.3M.","Full-year 2025 revenue guidance raised to $170M-$174M from continuing operations."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-106421","json":"https://secwatch.observer/filing/0001104659-25-106421.json","markdown":"https://secwatch.observer/filing/0001104659-25-106421.md","text":"https://secwatch.observer/filing/0001104659-25-106421.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465925106421/0001104659-25-106421-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465925106421/tm2530148d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:32:41.923329+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}